Q2 2023

Filed Aug 14, 2023 · 10-Q · 45 days after period end · 0001583771-23-000010

Q2 2023 · 10-Q

Revenue

$0.00

— vs Q2 2022

Net Income

-$14.08M

N/M vs Q2 2022

EPS Diluted

-$3.68

N/M vs Q2 2022

Operating Income-$14,165,630N/M

Operating Cash Flow

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	$0.00	$0.00	$0.00	$0.00
Net Income	-$14.08M	-$19.91M	-$7.67M	-$4.94M
EPS Diluted	-$3.68	-$5.22	-$0.10	-$0.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Hepion Pharmaceuticals, Inc. · CIK 1583771 · Engraved from SEC EDGAR